2025 Q3 -tulosraportti
64 päivää sittenTarjoustasot
Oslo Børs
Määrä
Osto
200
Myynti
Määrä
10
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 8 | - | - | ||
| 445 | - | - | ||
| 184 | - | - | ||
| 1 | - | - | ||
| 37 | - | - |
Ylin
44VWAP
Alin
41,005VaihtoMäärä
0,6 13 424
VWAP
Ylin
44Alin
41,005VaihtoMäärä
0,6 13 424
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 19.11.2025 | |
| 2025 Q2 -tulosraportti | 20.8.2025 | |
| 2025 Q1 -tulosraportti | 21.5.2025 | |
| 2024 Q4 -tulosraportti | 26.2.2025 | |
| 2024 Q3 -tulosraportti | 13.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·11 t sittenThere is no negative clinical news that explains the brutal fall. A peer-reviewed article was published in Gynecologic Oncology confirming that Radspherin was well tolerated in phase 1, without dose-limiting toxicity, that the recommended dose has been established, and that the radioactivity remains localized in the abdominal cavity as intended. After 12 months of follow-up, none of the patients had peritoneal recurrence. This is precisely why the randomized phase 2 study is now ongoing in Europe and the USA. There is almost no real turnover in the stock. The reverse stock split that has been adopted is also not a sign that something is “broken”, it is a formal requirement. On the Oslo Stock Exchange, a company cannot have a share price below 1 krone for an extended period (typically around one year) without having to take measures. A reverse stock split is therefore a technical measure to fulfill the exchange's requirements, not an assessment of the company's value. The price fall is not driven by documented failure in science or clinical results, but by low liquidity, pressure from Myrlid AS after the share issue (sold several million shares within three weeks in the market) and possibly general biotech skepticism. Here you can read the report: https://www.sciencedirect.com/science/article/pii/S0090825825011023
·1 t sittenDoes not change value, just fewer shares 4800/100= 48 shares (have had many thoughts and opinions about that reverse split and the ratio previously, will let it be)
·1 päivä sitten · MuokattuAs expected, now down by an additional 20 % within just one week. If anyone wants to understand how this situation arose, that the company's value has fallen from 52.- nok per share to now the equivalent of 40 øre without negative news being reported, they can, e.g., look up Hadean invest and the appearance of its representative in Oncoinvent management/influence. Also, this in connection with the founder's flight from the company. That's where the decline started. Why should this downturn stop? Hard facts are needed. But management is completely absent towards its small shareholders without the possibility of deeper insight. This despite them being fully aware of the "trashing" of this stock. There is a lack of comprehensive regulations in Norway for biotech stocks that protect small shareholders. How will Biotech in Norway ever become an attractive investment case when it rages there like in the wild west? In other words, end with oil and gas, no biotech, no significant agriculture. But then there's a bit of fish and tourism.... This will be a golden age to come, with almost everyone being hired as leaders in a dysfunctional state system. A nation that is supposed to save the world, but itself forgets to create a prosperous future for itself. Good luck!- ·1 päivä sittenOncoinvent researches new cancer treatment. They are developing Radspherin, a radiation therapy given after surgery to eliminate microscopic cancer cells, particularly in ovarian cancer and colorectal cancer. The treatment has shown promising results in phase 1 and phase 1/2a, and the company is now in a randomized phase 2 study in Europe and the USA. Oncoinvent is valued below its cash holdings. In December, they carried out an emission at 50 kroner (after share split) and raised 130 million kroner. Today's share price down at 40 kroner gives a market capitalization of only 185 million. The market thus values the research, the phase 2 study, the patents, the GMP production in Oslo, and the rest of the company at a negative value. Through the merger with BerGenBio, Oncoinvent acquired a tax-loss carryforward of approximately 2.15 billion kroner. It is also specified that the loss can be carried forward without time limitation, and that no deferred tax asset has been recognized because the company does not expect taxable profit in the short term. The market currently also values the tax benefit at zero. Oncoinvent is valued very defensively, given that the tax value in isolation has great value if they succeed further or are acquired by a profitable entity.
·1 päivä sittenCorrect, the company must have cash of around 200 mill NOK at the beginning of this year. By the end of 2026, the first interim analysis is expected from the randomized Phase 2b study and if Radspherin shows improved PFS vs placebo, for which there must be really good chances given the promising data from patients who have received 7MBq dosage (hardly any recurrence in the abdominal cavity where the drug works), then a partnership agreement must be relevant and a new share issue under completely different conditions. 
·1 päivä sittenNew updates and readouts for Radspherin (Oncoinvent) are expected in several rounds throughout 2026, based on the company's current clinical program and recent statements. Here is an overview of what you can expect going forward: 1. Results from the Phase 2 study (Ovarian Cancer) This is the most important milestone for the company right now. The Phase 2 study, investigating efficacy and safety in patients with ovarian cancer (peritoneal carcinomatosis), started recruitment in 2024 and is now fully underway at several hospitals, including Radiumhospitalet. Expected readout: The company has indicated that they expect results from this study during 2026. What they are looking for: The main focus is progression-free survival (PFS) compared to the control group receiving only standard treatment. 2. Long-term follow-up (Phase 1/2a) The company regularly publishes updates from its completed early-phase studies to show the duration of the treatment. Ovarian Cancer: Oncoinvent recently (December 2025) published 24-month data showing very promising results (only 10 % recurrence in the abdominal cavity at the recommended dose). New follow-up data may be presented at medical conferences throughout 2026. Colorectal Cancer: The latest official 18-month results were presented late in 2025. It is natural to expect further updated survival data during 2026. 3. Start of new studies Colorectal Cancer (Phase 2): Following positive results from Phase 1/2a, the company plans to start a larger Phase 2 study also for patients with colorectal cancer that has spread to the peritoneum. News about the study start here may come in the first half of 2026.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
64 päivää sittenUutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·11 t sittenThere is no negative clinical news that explains the brutal fall. A peer-reviewed article was published in Gynecologic Oncology confirming that Radspherin was well tolerated in phase 1, without dose-limiting toxicity, that the recommended dose has been established, and that the radioactivity remains localized in the abdominal cavity as intended. After 12 months of follow-up, none of the patients had peritoneal recurrence. This is precisely why the randomized phase 2 study is now ongoing in Europe and the USA. There is almost no real turnover in the stock. The reverse stock split that has been adopted is also not a sign that something is “broken”, it is a formal requirement. On the Oslo Stock Exchange, a company cannot have a share price below 1 krone for an extended period (typically around one year) without having to take measures. A reverse stock split is therefore a technical measure to fulfill the exchange's requirements, not an assessment of the company's value. The price fall is not driven by documented failure in science or clinical results, but by low liquidity, pressure from Myrlid AS after the share issue (sold several million shares within three weeks in the market) and possibly general biotech skepticism. Here you can read the report: https://www.sciencedirect.com/science/article/pii/S0090825825011023·1 t sittenDoes not change value, just fewer shares 4800/100= 48 shares (have had many thoughts and opinions about that reverse split and the ratio previously, will let it be)
- ·1 päivä sitten · MuokattuAs expected, now down by an additional 20 % within just one week. If anyone wants to understand how this situation arose, that the company's value has fallen from 52.- nok per share to now the equivalent of 40 øre without negative news being reported, they can, e.g., look up Hadean invest and the appearance of its representative in Oncoinvent management/influence. Also, this in connection with the founder's flight from the company. That's where the decline started. Why should this downturn stop? Hard facts are needed. But management is completely absent towards its small shareholders without the possibility of deeper insight. This despite them being fully aware of the "trashing" of this stock. There is a lack of comprehensive regulations in Norway for biotech stocks that protect small shareholders. How will Biotech in Norway ever become an attractive investment case when it rages there like in the wild west? In other words, end with oil and gas, no biotech, no significant agriculture. But then there's a bit of fish and tourism.... This will be a golden age to come, with almost everyone being hired as leaders in a dysfunctional state system. A nation that is supposed to save the world, but itself forgets to create a prosperous future for itself. Good luck!
- ·1 päivä sittenOncoinvent researches new cancer treatment. They are developing Radspherin, a radiation therapy given after surgery to eliminate microscopic cancer cells, particularly in ovarian cancer and colorectal cancer. The treatment has shown promising results in phase 1 and phase 1/2a, and the company is now in a randomized phase 2 study in Europe and the USA. Oncoinvent is valued below its cash holdings. In December, they carried out an emission at 50 kroner (after share split) and raised 130 million kroner. Today's share price down at 40 kroner gives a market capitalization of only 185 million. The market thus values the research, the phase 2 study, the patents, the GMP production in Oslo, and the rest of the company at a negative value. Through the merger with BerGenBio, Oncoinvent acquired a tax-loss carryforward of approximately 2.15 billion kroner. It is also specified that the loss can be carried forward without time limitation, and that no deferred tax asset has been recognized because the company does not expect taxable profit in the short term. The market currently also values the tax benefit at zero. Oncoinvent is valued very defensively, given that the tax value in isolation has great value if they succeed further or are acquired by a profitable entity.·1 päivä sittenCorrect, the company must have cash of around 200 mill NOK at the beginning of this year. By the end of 2026, the first interim analysis is expected from the randomized Phase 2b study and if Radspherin shows improved PFS vs placebo, for which there must be really good chances given the promising data from patients who have received 7MBq dosage (hardly any recurrence in the abdominal cavity where the drug works), then a partnership agreement must be relevant and a new share issue under completely different conditions.
- ·1 päivä sittenNew updates and readouts for Radspherin (Oncoinvent) are expected in several rounds throughout 2026, based on the company's current clinical program and recent statements. Here is an overview of what you can expect going forward: 1. Results from the Phase 2 study (Ovarian Cancer) This is the most important milestone for the company right now. The Phase 2 study, investigating efficacy and safety in patients with ovarian cancer (peritoneal carcinomatosis), started recruitment in 2024 and is now fully underway at several hospitals, including Radiumhospitalet. Expected readout: The company has indicated that they expect results from this study during 2026. What they are looking for: The main focus is progression-free survival (PFS) compared to the control group receiving only standard treatment. 2. Long-term follow-up (Phase 1/2a) The company regularly publishes updates from its completed early-phase studies to show the duration of the treatment. Ovarian Cancer: Oncoinvent recently (December 2025) published 24-month data showing very promising results (only 10 % recurrence in the abdominal cavity at the recommended dose). New follow-up data may be presented at medical conferences throughout 2026. Colorectal Cancer: The latest official 18-month results were presented late in 2025. It is natural to expect further updated survival data during 2026. 3. Start of new studies Colorectal Cancer (Phase 2): Following positive results from Phase 1/2a, the company plans to start a larger Phase 2 study also for patients with colorectal cancer that has spread to the peritoneum. News about the study start here may come in the first half of 2026.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
200
Myynti
Määrä
10
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 8 | - | - | ||
| 445 | - | - | ||
| 184 | - | - | ||
| 1 | - | - | ||
| 37 | - | - |
Ylin
44VWAP
Alin
41,005VaihtoMäärä
0,6 13 424
VWAP
Ylin
44Alin
41,005VaihtoMäärä
0,6 13 424
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 19.11.2025 | |
| 2025 Q2 -tulosraportti | 20.8.2025 | |
| 2025 Q1 -tulosraportti | 21.5.2025 | |
| 2024 Q4 -tulosraportti | 26.2.2025 | |
| 2024 Q3 -tulosraportti | 13.11.2024 |
2025 Q3 -tulosraportti
64 päivää sittenUutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 19.11.2025 | |
| 2025 Q2 -tulosraportti | 20.8.2025 | |
| 2025 Q1 -tulosraportti | 21.5.2025 | |
| 2024 Q4 -tulosraportti | 26.2.2025 | |
| 2024 Q3 -tulosraportti | 13.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·11 t sittenThere is no negative clinical news that explains the brutal fall. A peer-reviewed article was published in Gynecologic Oncology confirming that Radspherin was well tolerated in phase 1, without dose-limiting toxicity, that the recommended dose has been established, and that the radioactivity remains localized in the abdominal cavity as intended. After 12 months of follow-up, none of the patients had peritoneal recurrence. This is precisely why the randomized phase 2 study is now ongoing in Europe and the USA. There is almost no real turnover in the stock. The reverse stock split that has been adopted is also not a sign that something is “broken”, it is a formal requirement. On the Oslo Stock Exchange, a company cannot have a share price below 1 krone for an extended period (typically around one year) without having to take measures. A reverse stock split is therefore a technical measure to fulfill the exchange's requirements, not an assessment of the company's value. The price fall is not driven by documented failure in science or clinical results, but by low liquidity, pressure from Myrlid AS after the share issue (sold several million shares within three weeks in the market) and possibly general biotech skepticism. Here you can read the report: https://www.sciencedirect.com/science/article/pii/S0090825825011023·1 t sittenDoes not change value, just fewer shares 4800/100= 48 shares (have had many thoughts and opinions about that reverse split and the ratio previously, will let it be)
- ·1 päivä sitten · MuokattuAs expected, now down by an additional 20 % within just one week. If anyone wants to understand how this situation arose, that the company's value has fallen from 52.- nok per share to now the equivalent of 40 øre without negative news being reported, they can, e.g., look up Hadean invest and the appearance of its representative in Oncoinvent management/influence. Also, this in connection with the founder's flight from the company. That's where the decline started. Why should this downturn stop? Hard facts are needed. But management is completely absent towards its small shareholders without the possibility of deeper insight. This despite them being fully aware of the "trashing" of this stock. There is a lack of comprehensive regulations in Norway for biotech stocks that protect small shareholders. How will Biotech in Norway ever become an attractive investment case when it rages there like in the wild west? In other words, end with oil and gas, no biotech, no significant agriculture. But then there's a bit of fish and tourism.... This will be a golden age to come, with almost everyone being hired as leaders in a dysfunctional state system. A nation that is supposed to save the world, but itself forgets to create a prosperous future for itself. Good luck!
- ·1 päivä sittenOncoinvent researches new cancer treatment. They are developing Radspherin, a radiation therapy given after surgery to eliminate microscopic cancer cells, particularly in ovarian cancer and colorectal cancer. The treatment has shown promising results in phase 1 and phase 1/2a, and the company is now in a randomized phase 2 study in Europe and the USA. Oncoinvent is valued below its cash holdings. In December, they carried out an emission at 50 kroner (after share split) and raised 130 million kroner. Today's share price down at 40 kroner gives a market capitalization of only 185 million. The market thus values the research, the phase 2 study, the patents, the GMP production in Oslo, and the rest of the company at a negative value. Through the merger with BerGenBio, Oncoinvent acquired a tax-loss carryforward of approximately 2.15 billion kroner. It is also specified that the loss can be carried forward without time limitation, and that no deferred tax asset has been recognized because the company does not expect taxable profit in the short term. The market currently also values the tax benefit at zero. Oncoinvent is valued very defensively, given that the tax value in isolation has great value if they succeed further or are acquired by a profitable entity.·1 päivä sittenCorrect, the company must have cash of around 200 mill NOK at the beginning of this year. By the end of 2026, the first interim analysis is expected from the randomized Phase 2b study and if Radspherin shows improved PFS vs placebo, for which there must be really good chances given the promising data from patients who have received 7MBq dosage (hardly any recurrence in the abdominal cavity where the drug works), then a partnership agreement must be relevant and a new share issue under completely different conditions.
- ·1 päivä sittenNew updates and readouts for Radspherin (Oncoinvent) are expected in several rounds throughout 2026, based on the company's current clinical program and recent statements. Here is an overview of what you can expect going forward: 1. Results from the Phase 2 study (Ovarian Cancer) This is the most important milestone for the company right now. The Phase 2 study, investigating efficacy and safety in patients with ovarian cancer (peritoneal carcinomatosis), started recruitment in 2024 and is now fully underway at several hospitals, including Radiumhospitalet. Expected readout: The company has indicated that they expect results from this study during 2026. What they are looking for: The main focus is progression-free survival (PFS) compared to the control group receiving only standard treatment. 2. Long-term follow-up (Phase 1/2a) The company regularly publishes updates from its completed early-phase studies to show the duration of the treatment. Ovarian Cancer: Oncoinvent recently (December 2025) published 24-month data showing very promising results (only 10 % recurrence in the abdominal cavity at the recommended dose). New follow-up data may be presented at medical conferences throughout 2026. Colorectal Cancer: The latest official 18-month results were presented late in 2025. It is natural to expect further updated survival data during 2026. 3. Start of new studies Colorectal Cancer (Phase 2): Following positive results from Phase 1/2a, the company plans to start a larger Phase 2 study also for patients with colorectal cancer that has spread to the peritoneum. News about the study start here may come in the first half of 2026.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
200
Myynti
Määrä
10
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 8 | - | - | ||
| 445 | - | - | ||
| 184 | - | - | ||
| 1 | - | - | ||
| 37 | - | - |
Ylin
44VWAP
Alin
41,005VaihtoMäärä
0,6 13 424
VWAP
Ylin
44Alin
41,005VaihtoMäärä
0,6 13 424
Välittäjätilasto
Dataa ei löytynyt